While not constitutively expressed in the healthy human brain, sustained TRAIL immunoreactivity has been detected nearby Aβ plaques in human post-mortem AD brain [11], suggesting the importance to exploit TRAIL as a therapeutic target. Here, TNFSF10 is linked to Alzheimer disease.